GlaxoSmithKline Consumer Nigeria Plc manufactures, markets, and distributes of consumer healthcare and pharmaceutical products in Nigeria.
Price History & Performance
|Historical stock prices|
|Current Share Price||₦6.50|
|52 Week High||₦5.35|
|52 Week Low||₦8.70|
|1 Month Change||7.44%|
|3 Month Change||5.69%|
|1 Year Change||16.07%|
|3 Year Change||-48.82%|
|5 Year Change||-58.81%|
|Change since IPO||49.36%|
Recent News & Updates
|GLAXOSMITH||NG Pharmaceuticals||NG Market|
Return vs Industry: GLAXOSMITH underperformed the NG Pharmaceuticals industry which returned 37.3% over the past year.
Return vs Market: GLAXOSMITH underperformed the NG Market which returned 40.1% over the past year.
Stable Share Price: GLAXOSMITH is not significantly more volatile than the rest of NG stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: GLAXOSMITH's weekly volatility (5%) has been stable over the past year.
About the Company
GlaxoSmithKline Consumer Nigeria Plc manufactures, markets, and distributes of consumer healthcare and pharmaceutical products in Nigeria. It operates through two segments, Consumer Healthcare and Pharmaceuticals. The Consumer Healthcare segment offers oral care, over-the-counter (OTC) medicine, and nutritional healthcare products.
GlaxoSmithKline Consumer Nigeria Fundamentals Summary
|GLAXOSMITH fundamental statistics|
Is GLAXOSMITH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GLAXOSMITH income statement (TTM)|
|Cost of Revenue||₦15.52b|
Last Reported Earnings
Sep 30, 2020
Next Earnings Date
|Earnings per share (EPS)||0.70|
|Net Profit Margin||3.93%|
How did GLAXOSMITH perform over the long term?See historical performance and comparison
6.2%Current Dividend Yield
Is GlaxoSmithKline Consumer Nigeria undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GLAXOSMITH (NGN6.5) is trading below our estimate of fair value (NGN221.4)
Significantly Below Fair Value: GLAXOSMITH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GLAXOSMITH's PE Ratio (9.3x) is in line with the African Pharmaceuticals industry average.
PE vs Market: GLAXOSMITH is poor value based on its PE Ratio (9.3x) compared to the NG market (7.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GLAXOSMITH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GLAXOSMITH is good value based on its PB Ratio (0.9x) compared to the XF Pharmaceuticals industry average (1.6x).
How is GlaxoSmithKline Consumer Nigeria forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlaxoSmithKline Consumer Nigeria has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has GlaxoSmithKline Consumer Nigeria performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: GLAXOSMITH has high quality earnings.
Growing Profit Margin: GLAXOSMITH's current net profit margins (3.9%) are higher than last year (3.4%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GLAXOSMITH's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare GLAXOSMITH's past year earnings growth to its 5-year average.
Earnings vs Industry: GLAXOSMITH earnings growth over the past year (20.4%) exceeded the Pharmaceuticals industry 10%.
Return on Equity
High ROE: GLAXOSMITH's Return on Equity (9.4%) is considered low.
How is GlaxoSmithKline Consumer Nigeria's financial position?
Financial Position Analysis
Short Term Liabilities: GLAXOSMITH's short term assets (NGN20.1B) exceed its short term liabilities (NGN13.3B).
Long Term Liabilities: GLAXOSMITH has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: GLAXOSMITH is debt free.
Reducing Debt: GLAXOSMITH had no debt 5 years ago.
Debt Coverage: GLAXOSMITH has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GLAXOSMITH has no debt, therefore coverage of interest payments is not a concern.
What is GlaxoSmithKline Consumer Nigeria current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GLAXOSMITH's dividend (6.15%) is higher than the bottom 25% of dividend payers in the NG market (3.3%).
High Dividend: GLAXOSMITH's dividend (6.15%) is low compared to the top 25% of dividend payers in the NG market (7.31%).
Stability and Growth of Payments
Stable Dividend: GLAXOSMITH's dividend payments have been volatile in the past 10 years.
Growing Dividend: GLAXOSMITH's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (76.2%), GLAXOSMITH's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Kunle Oyelana serves as Managing Director at GlaxoSmithKline Consumer Nigeria Plc. He had been General Manager at GlaxoSmithKline Consumer Nigeria Plc since August 2019. He served as Managing Director...
Experienced Management: GLAXOSMITH's management team is considered experienced (2.5 years average tenure).
Experienced Board: GLAXOSMITH's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
GlaxoSmithKline Consumer Nigeria Plc's employee growth, exchange listings and data sources
- Name: GlaxoSmithKline Consumer Nigeria Plc
- Ticker: GLAXOSMITH
- Exchange: NGSE
- Founded: 1971
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₦7.773b
- Shares outstanding: 1.20b
- Website: https://www.gsk.com/ng
Number of Employees
- GlaxoSmithKline Consumer Nigeria Plc
- 1, Industrial Avenue
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 15:21|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.